Cargando…
Expression of immune checkpoint PD-1 in non-small cell lung cancer is associated with tumor cell DNA-dependent protein kinase
Immunotherapy using immune checkpoint inhibitors has demonstrated durable responses and has significantly improved survival in patients with non-small cell lung cancer (NSCLC). Moreover, immunotherapy is increasingly used in combination with cytotoxic treatments such as chemotherapy and radiotherapy...
Autores principales: | Saar, Marika, Narits, Jaanika, Mägi, Laura, Aaspõllu, Hardi, Vapper, Annett, Kase, Marju, Minajeva, Ave, Vooder, Tõnu, Tamm, Hannes, Buldakov, Maksim, Lavõgina, Darja, Jaal, Jana |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8375025/ https://www.ncbi.nlm.nih.gov/pubmed/34462666 http://dx.doi.org/10.3892/mco.2021.2369 |
Ejemplares similares
-
Immune checkpoint inhibitors modulate the cytotoxic effect of chemotherapy in lung adenocarcinoma cells
por: Saar, Marika, et al.
Publicado: (2023) -
PD-L1 induction in tumor tissue after hypofractionated thoracic radiotherapy for non-small cell lung cancer
por: Narits, Jaanika, et al.
Publicado: (2020) -
Impact of CD133 positive stem cell proportion on survival in patients with glioblastoma multiforme
por: Kase, Marju, et al.
Publicado: (2013) -
VEGFR-2 Expression in Glioblastoma Multiforme Depends on Inflammatory Tumor Microenvironment
por: Jaal, Jana, et al.
Publicado: (2015) -
Impact of Blood Vessel Quantity and Vascular Expression of CD133 and ICAM-1 on Survival of Glioblastoma Patients
por: Minajeva, Ave, et al.
Publicado: (2017)